Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by GCGR is a glucagon receptor that is important in controlling blood glucose levels. Additionally we are shipping Glucagon Receptor Proteins (5) and Glucagon Receptor Kits (1) and many more products for this protein.
Showing 10 out of 98 products:
Human Polyclonal Glucagon Receptor Primary Antibody for IHC (p) - ABIN271047
Mighiu, Yue, Filippi, Abraham, Chari, Lam, Yang, Christian, Charron, Lam: Hypothalamic glucagon signaling inhibits hepatic glucose production. in Nature medicine 2013
Show all 2 references for ABIN271047
Human Polyclonal Glucagon Receptor Primary Antibody for ELISA - ABIN314296
Sørensen, Winzell, Brand, Fosgerau, Gelling, Nishimura, Ahren: Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. in Diabetes 2006
Human Polyclonal Glucagon Receptor Primary Antibody for IF (p), IHC (p) - ABIN751528
Rafacho, Gonçalves-Neto, Santos-Silva, Alonso-Magdalena, Merino, Taboga, Carneiro, Boschero, Nadal, Quesada: Pancreatic alpha-cell dysfunction contributes to the disruption of glucose homeostasis and compensatory insulin hypersecretion in glucocorticoid-treated rats. in PLoS ONE 2014
2.5 A crystal structure of human GCGR in complex with the antagonist MK-0893, which is found to bind to an allosteric site outside the seven transmembrane helical bundle in a position between TM6 and TM7 extending into the lipid bilayer
Molecular dynamics and disulfide crosslinking studies suggest that apo (show C9orf3 Antibodies)-GCGR can adopt both an open and closed conformation associated with extensive contacts between the ECD (show SHFM1 Antibodies) and 7TM domain. Glucagon (show GCG Antibodies) binds to GCGR by a conformational selection mechanism.
glucagon (show GCG Antibodies) cell adenomatosis with GCGR germline mutations seems to follow an autosomal-recessive trait.
Using a real-time time-resolved FRET-based internalization assay, we show that GLP-1R (show GLP1R Antibodies), GIPR (show GIPR Antibodies), and GCGR internalize with differential properties
crystal structure of the seven transmembrane helical domain of human GCGR at 3.4 A resolution, and a hybrid model of glucagon (show GCG Antibodies) bound to GCGR to understand the molecular recognition of the receptor for its native ligand
Letter/Case Report: nonfunctional glucagon (show GCG Antibodies) cell adenomatosis with no detectable glucagon receptor mutations.
GRA1 is a potent glucagon receptor antagonist with strong antihyperglycemic efficacy in preclinical models and prominent effects on hepatic gene-expression related to amino acid metabolism
F22, V23, M27, and D15 (show MRPL16 Antibodies) of GCGR are the most important residues for glucagon (show GCG Antibodies) binding.
in addition to activation of the classic cAMP/protein kinase A (PKA) pathway, activation of GCGR also induced beta-catenin (show CTNNB1 Antibodies) stabilization and activated beta-catenin (show CTNNB1 Antibodies)-mediated transcription
analysis of glucagon receptor antagonists with reduced molecular weight and lipophilicity
glucagon receptor antagonist improves glycemia in diet-induced obese angptl4 (show ANGPTL4 Antibodies) knockout mice without increasing glucagon (show GCG Antibodies) levels or alpha-cell proliferation, underscoring the importance of this protein.
Data indicate that the exocrine pancreas in the glucagon receptor Gcgr-/- mice exhibited larger nuclear size than in WT or heterozygous controls, most obviously at old ages.
Simultaneous and sufficient activation of GLP1R (show GLP1R Antibodies) is required to reduce GCCR (show NR3C1 Antibodies) mediated blood glucose elevation following administration of a GLP1R (show GLP1R Antibodies)/GCGR co-agonist.
Knockdown of liver glucagon receptor in mice reduces blood glucose and increases blood LDL levels.
Gcgr(-/-) mice became lethargic (show CACNB4 Antibodies) & cachexic & died early. Autopsy revealed numerous PNETs up to 15 mm in diameter in most well-preserved Gcgr(-/-) pancreata.
Data suggest that GcgR activation raises hepatic expression of fibroblast growth factor 21 (FGF21 (show FGF21 Antibodies)) and increases circulating levels of FGF21 (show FGF21 Antibodies); GcgR activation induces body weight loss and stimulates lipid metabolism.
These results suggest that a circulating factor generated after disruption of hepatic Gcgr signaling can increase alpha-cell proliferation independent of direct pancreatic input.
Data suggest that both Gcgr activity and glucagon-like peptide 1 (show GCG Antibodies)/Glp1r (show GLP1R Antibodies) signal transduction in central nervous system are involved in control of interscapular brown adipose tissue thermogenesis.
A novel transgenic mouse was generated which had muscle specific (show EIF3K Antibodies) expression of glucagon receptor. The transgenic mice maintained an appropriate ratio of glucagon (show GCG Antibodies) to insulin (show INS Antibodies), which appears important in maintaining glucose homeostasis.
The protein encoded by this gene is a glucagon receptor that is important in controlling blood glucose levels. Defects in this gene are a cause of non-insulin-dependent diabetes mellitus (NIDDM).
, glucagon receptor-like
, glucagon receptor perhaps same as Niddm3